Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the company. Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024. Cash position of $54.1M provides runway through key near-term milestones, into 2025
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD:
- Rising High: Exclusive talk with house of brands Carma HoldCo
- RLMD Upcoming Earnings Report: What to Expect?
- Rising High: RIV Capital provides update on revenue, synergy realization
- Rising High: Exclusive talk with vape tech developer Ispire Technology
- Rising High: RIV Capital, Cansortium launch MOODS brand in New York